Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion:study protocol for an open-label, non-randomised, prospective, single-arm trial by Laing, Richard W et al.
 
 
Viability testing and transplantation of marginal
livers (VITTAL) using normothermic machine
perfusion
Laing, Richard; Mergental, Hynek; Yap, Christina; Kirkham, Amanda; Whilku, Manpreet;
Barton, Darren; Curbishley, Stuart; Boteon, Yuri; Neil, Desley; Hubscher, Stefan; Perera,





Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Laing, RW, Mergental, H, Yap, C, Kirkham, A, Whilku, M, Barton, D, Curbishley, S, Boteon, YL, Neil, DA,
Hübscher, SG, Perera, MTPR, Muiesan, P, Isaac, J, Roberts, KJ, Cilliers, H, Afford, SC & Mirza, DF 2017,
'Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study
protocol for an open-label, non-randomised, prospective, single-arm trial', BMJ open, vol. 7, no. 11, e017733.
https://doi.org/10.1136/bmjopen-2017-017733
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
 1Laing RW, et al. BMJ Open 2017;7:e017733. doi:10.1136/bmjopen-2017-017733
Open Access 
AbstrAct
Introduction The use of marginal or extended criteria 
donor livers is increasing. These organs carry a greater 
risk of initial dysfunction and early failure, as well as 
inferior long-term outcomes. As such, many are rejected 
due to a perceived risk of use and use varies widely 
between centres. Ex situ normothermic machine perfusion 
of the liver (NMP-L) may enable the safe transplantation of 
organs that meet defined objective criteria denoting their 
high-risk status and are currently being declined for use by 
all the UK transplant centres.
Methods and analysis Viability testing and 
transplantation of marginal livers is an open-label, non-
randomised, prospective, single-arm trial designed to 
determine whether currently unused donor livers can be 
salvaged and safely transplanted with equivalent outcomes 
in terms of patient survival. The procured rejected 
livers must meet predefined criteria that objectively 
denote their marginal condition. The liver is subjected to 
NMP-L following a period of static cold storage. Organs 
metabolising lactate to ≤2.5 mmol/L within 4 hours of the 
perfusion commencing in combination with two or more 
of the following parameters—bile production, metabolism 
of glucose, a hepatic arterial flow rate ≥150 mL/min and 
a portal venous flow rate ≥500 mL/min, a pH ≥7.30 and/or 
maintain a homogeneous perfusion—will be considered 
viable and transplanted into a suitable consented recipient. 
The coprimary outcome measures are the success rate 
of NMP-L to produce a transplantable organ and 90-day 
patient post-transplant survival.
Ethics and dissemination The protocol was approved 
by the National Research Ethics Service (London—
Dulwich Research Ethics Committee, 16/LO/1056), 
the Medicines and Healthcare Products Regulatory 
Agency and is endorsed by the National Health Service 
Blood and Transplant Research, Innovation and Novel 
Technologies Advisory Group. The findings of this trial 
will be disseminated through national and international 
presentations and peer-reviewed publications.
trial registration number NCT02740608; Pre-results.
IntroductIon
Liver transplantation
Liver transplantation is a highly successful 
treatment for end-stage liver disease, fulmi-
nant hepatic failure and early-stage primary 
liver cancer. Deaths from liver disease have 
soared by 40% in a decade and continue 
to rise. Liver disease kills 11 000 a year in 
England and the average age of death from 
liver disease (59 years) continues to decrease.1 
Over the past 50 years, transplant techniques 
and outcomes have greatly improved and 
5-year survival rates of 70%–80% mean that 
transplantation has become the mainstay 
of treatment for an increasing number of 
patients with chronic liver disease, metabolic 
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Protocol
strengths and limitations of this study
 ► The study will answer the question: ‘Can ex situ end 
ischaemic normothermic machine perfusion safely 
increase the number of transplantable livers?’
 ► The study aims to establish objective liver viability 
criteria and biomarkers that may enable point-of-
care assessment of liver quality.
 ► The study has clearly defined criteria characterising 
the discarded organs.
 ► Incorporation of an adaptive three-stage trial design 
provides opportunities to assess patients’ safety, 
allowing for early trial termination if necessary.
 ► The trial includes low and moderate risk recipients 
only—the suitability for high-risk recipients will 
require further testing.
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disorders, acute liver failure and malignancy. As such, 
the demand for donor livers greatly exceeds supply and 
approximately 20% of patients die while awaiting trans-
plantation.2 In Europe, the most common indications 
for liver transplantation are cirrhosis (68%), malignancy 
(14%) and acute hepatic failure (8%). The main causes 
for cirrhosis in Europe are the hepatotropic viruses 
and alcohol-related liver disease.3 Non-alcoholic fatty 
liver disease is an emergent cause and despite health 
campaigns, the incidence continues to rise. In the UK, it 
is predicted that the incidences of end-stage liver disease 
and hepatocellular carcinoma will increase substan-
tially during the next decade, exacerbating the existing 
shortage of donor livers.
the uK liver transplant programme
Between March 2015 and April 2016, there were 1161 new 
waiting list registrations in the UK, and 878 transplants 
were carried out. Of the 621 patients on the list as of April 
2015, 22% died or were removed from the list (n=135) 
due to deteriorating health.4 This is reflected across other 
countries to the extent that a patient is now more likely to 
die within the first 12 months of being listed than the first 
12 months’ post-transplant.5 Over the past decade, there 
has been a very modest increase in the use of standard or 
‘ideal’ organ donors (those retrieved from young donors 
following a diagnosis of brain stem death, (DBD)). In 
response, centres have use donors following circulatory 
death (DCD) and suboptimal ‘marginal’ or ‘extended 
criteria’ donors (those of older age, livers with a presence 
of steatosis, etc).
responding to the shortage
There are several ways to respond to the shortage. Organ 
donation policies are undergoing changes; however, there 
is a lack of well-controlled scientific evidence on which to 
base decisions regarding policy-making and opinions are 
strong and divided. Spain has the highest organ donation 
rates and operates an opt-out system, however, the rise in 
rates only started approximately 10 years after the system’s 
introduction. Wales is the most recent country to go down 
this route, however unlike in Spain, next of kin consent is 
still required before patients can become organ donors. 
More likely, the increased Spanish donation rates are due 
to a combination of factors—the creation of a transplant 
coordination network that operates at hospital, regional 
and national levels, the placement of transplant coordi-
nators at each procurement hospital and the improve-
ment in the quality of information received by the public. 
Living donation is one potential means to increase the 
number of liver transplants, using surgical techniques 
developed for liver resection and ‘liver splitting’ (which 
uses a single liver for transplantation into two recipients). 
The major limitations are most patients do not have a 
willing or suitable living donor and there are concerns 
about the risks to the healthy donor. The reported risk of 
donor death is estimated at 0.2% but the risk of serious 
complications is much higher.6 7 Although programmes 
have had some success in countries without deceased 
donor programmes, living donor transplantation will be 
unlikely to have a significant impact on the shortage of 
donor livers in most countries.
the use of ‘marginal’ or ‘extended criteria’ donors
As discussed, a rising proportion of transplants are 
carried out using ‘marginal’ or ‘extended criteria’ grafts, 
procured from obese or elderly donors with multiple 
comorbidities.8 These livers are significantly more suscep-
tible to cold storage-related ischaemic injury, which 
increases the risk of graft failure and recipient morbidity 
and mortality. Reflecting the issues with these suboptimal 
grafts, in 2014/2015, of 1282 solid organ donors, only 
924 (72.1%) livers were deemed suitable for retrieval and 
only 812 (63.3%) were subsequently transplanted.9 The 
duration of the functional warm ischaemic time (FWIT) 
is an important determinant of outcome. The recent 
document ‘Donation After Circulatory Death' published 
by a steering group on behalf of the British Transplan-
tation Society and Intensive Care Society suggested that 
the stand-down time from the onset of functional warm 
ischaemia for DCD liver transplantation was 30 min 
(although 20 min is ideal), and that age was an important 
factor. Because of this, a number of livers will be retrieved 
from DCDs that fall into the ‘marginal donor’ category 
and may not go on to be transplanted.10
Several donor parameters have been identified as rela-
tive risk factors for poor outcome including age, steatosis, 
DCD donation, split livers and prolonged cold ischaemia 
time (>12 hours). These were all developed using North 
American data and formulated into an algorithm known 
as the Donor Risk Index (DRI) and later validated using 
European data.11 12 The British Transplantation Society 
have published their own guidelines on the use of donor 
organs and use criteria in table 1 to distinguish between 
grafts of varying quality.
organ preservation
The current standard of donor liver preservation is based 
on static cold storage (SCS).13 During SCS, organs are 
flushed and cooled with specific chilled preservation 
solutions (University of Wisconsin solution is used most 
commonly although histidine–tryptophan–ketogluta-
rate (HTK) solution is also used less widely) and ice is 
added to the abdominal cavity. After retrieval, the organ 
is placed in fluid-filled sterile plastic bags for transpor-
tation and stored in preservation solution within an ice 
box until transplantation. Although the available pres-
ervation solutions differ in chemical composition, their 
function is essentially the same. The hypothermia aims to 
reduce the liver’s metabolic activity and the solution aims 
to reduce the cellular swelling. This is a consequence 
of anaerobic metabolism resulting in depletion of ATP 
stores leading to influx of free calcium and activation of 
phospholipases.14 Cooling the organ slows metabolism 
approximately 12-fold but cannot prevent its dysfunc-
tion and the eventual destruction of cellular integrity. 
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Table 1 Criteria for donor quality as per British Transplantation Society UK Guidelines for donors after circulatory death
Good livers—all should be 
used (DBDs and DCDs)





to using liver as donor organ
 ► Age<50
 ► Normal LFTs
 ► <5 days on ICU
 ► Low levels of inotropic support
 ► <30% steatosis
 ► No active sepsis
 ► Age<50 years
 ►Weight<100 kg
 ► FWIT<20 min
 ► CIT<8 hours
 ► <15% steatosis
 ► ICU stay<5 days
 ► Age >50 years
 ►Weight >100 kg
 ► FWIT 20–30 min
 ► CIT 8–12 hours
 ► >15% steatosis
 ► ICU stay >5 days
 ► DCD with macrovesicular 
steatosis >30%
 ► ESLD
 ► Acute liver failure
 ► Acute liver injury that is not 
improving
CIT, cold ischaemic time; DBD, donor following brain death; DCD, donor following circulatory death; ESLD, end-stage liver disease; FWIT, 
functional warm ischaemic time; ICU, intensive care stay; LFTs, liver function tests.
Ischaemia reperfusion is an important factor influencing 
graft outcome.15 The ischaemic phase starts early in the 
procurement process (swings in blood pressure following 
brain death or due to the functional warm ischaemic time 
in non-heart beating donors) and triggers a complex 
cascade of cellular and molecular events including the 
release of proinflammatory mediators and chemotaxis 
of cell types that initiate progressive immunological 
processes. During the reperfusion phase, ‘the reflow 
paradox’ causes infiltration of the tissues by leucocytes 
and cellular injury occurs through a series of pathways 
that include lipid peroxidation and the creation of reac-
tive oxygen species16 The most common manifestation of 
the ischaemia-reperfusion process is delayed graft func-
tion, which is the inability of the organ to fulfil the physi-
ological needs of the recipient and is associated with graft 
failure, retransplantation and death.17Static cold storage 
therefore is unable to reverse the injury sustained during 
donor death and procurement, causes injury due to the 
cooling process, limits the preservation time and prevents 
physiological assessment prior to transplantation.
In situ organ reconditioning
To reverse or diminish the injury, many cytoprotective 
strategies have been tested in experimental models of 
transplantation and several have been shown to have ther-
apeutic potential, including gene therapy,18 19 cytokine 
or growth factor administration,20–22 vasodilating agents 
and ischaemic preconditioning.23 24 Treatment of the 
organ during preservation has major logistic and ethical 
advantages over any attempt to achieve the same effects 
by treating the donor (therapeutic interventions before 
declaration of death are not currently permitted unless 
they are of potential benefit to the donor). Recently, 
there has been published early experience with normo-
thermic regional perfusion of DCD donors, nevertheless 
the feasibility and benefit of this experimental approach 
is yet to be shown.25
normothermic machine perfusion of the liver
Bretschneider and Starzl first attempted machine 
perfusion of the liver in the late 1960s. Although hypo-
thermic machine perfusion (HMP) has been shown 
some promise in clinical studies, normothermic machine 
perfusion of the liver (NMP-L) combats the limitations 
of SCS previously described by aiming to maintain the 
organ at the body's natural temperature while providing 
oxygen, nutrition and the essential substrates necessary 
for adequate cellular metabolism. Providing a homeo-
static environment theoretically enables us to extend our 
storage period and test the organs physiological parame-
ters. To date, only one clinical trial of 20 adult recipients 
of livers maintained by HMP has been published showing 
a reduction in early graft dysfunction (5% vs 25% p<0.08) 
as well as a significant reduction in serum injury markers 
in the HMP group. A joint pilot trial between Oxford 
University, King’s College Hospital London and Univer-
sity Hospitals Birmingham Foundation Trust (UHBFT) 
recruited 20 patients into an NMP-L phase I study and 
concluded the procedure was feasible and safe when used 
on current conventional donor acceptance criteria.26 
Following this, a 220-patient phase III international clin-
ical trial entitled ‘consortium for organ preservation in 
Europe (COPE) work package 2 (WP2)’ has completed 
recruitment and the results are eagerly awaited. The Liver 
Unit at University Hospital Birmingham NHS Foundation 
Trust contributed to this multicentre international trial 
by randomising 50% of the study patients.
Our group believes NMP-L enables the donor organ 
to be functionally assessed, thereby increasing transplant 
safety. It can also extend organ preservation times to 
improve transplant logistics and donor organ use. There 
are several devices available on the market, but only the 
OrganOx metra has been widely used in the clinical 
transplant setting.26 Our team has performed over 70 
liver transplants with grafts preserved on this machine 
and has gained broad experience by using this device. 
The OrganOx metra is the leading device in terms of the 
number of clinical transplants undertaken, with more 
than 100 machine-perfused livers transplanted in the 
phase III randomised European trial, together with 20 
livers in the phase I safety study and further ongoing trials 
in North America. For these reasons, we have decided to 
use the OrganOx metra device for the proposed study.
The device consists of a unit that cradles the liver, a 
perfusate reservoir, oxygenators, pumps operating at 
physiological pressures and a closed tubing system that 
connects the unit to the portal vein, hepatic artery and 
vena cava. The constituents of the perfusate can vary but 
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generally consist of whole blood for oxygen carriage, 
sources of nutrition (glucose, insulin, amino acids), anti-
thrombotic agents (heparin, epoprostenol), antibiotics 
and acid-base agents which help reduce cellular oedema, 
cholestasis, microvascular injury and the effects of free 
radicals.
benefits of nMP-L
NMP-L does not simply benefit marginal DCD organs 
that have been exposed to a damaging FWIT. DBD is a 
catastrophic physiological event associated with profound 
hypotension (parasympathetic response) followed by 
hypertension, tachycardia and high levels of circulating 
catecholamines (sympathetic surge) followed by another 
reduction in the sympathetic outflow. These dramatic 
swings can cause significant graft ischaemia prior to 
retrieval. Diabetes insipidus occurs in 70%–80% of brain 
dead patients causing severe hypernatraemia (associated 
with primary liver graft non-function), hypokalaemia, 
hypocalcaemia, hypophosphataemia and hypomagne-
saemia.27 28 Pirenne et al described seven cases when livers 
from DBDs between 70 and 80 years old were used with 
‘favourable outcomes’.29 More recently, groups from 
Italy have reported excellent outcomes using grafts from 
octogenarian donors.30 31 NMP-L could however play an 
important role in preconditioning and assessing such 
organs prior to transplantation.
Hellinger et al were unable to identify a benefit using 
NMP-L in 1997; however, it was the first study of its kind.32 
In 2001, Schon used NMP-L to preserve and recondition 
livers that had been exposed to 1 hour of warm ischaemia. 
These livers were then transplanted into pigs which all 
survived longer than 7 days. The group that received livers 
preserved using SCS had no survivors.33 Several studies 
have been published by the Oxford group, responsible 
for OrganOx metra. Imber et al published results from 
a study on a porcine model comparing NMP-L with SCS 
controls. They showed livers preserved using NMP-L were 
significantly superior (p<0.05) to SCS livers ‘in terms of 
bile production, factor V production, glucose metab-
olism and galactose clearance’, while SCS livers had 
higher perfusate levels of hepatocellular enzymes and 
more cellular damage.34 The same year, they successfully 
perfused and maintained five porcine livers for 72 hours, 
managing to maintain normal physiological parameters, 
pH, protein synthesis and histological architecture.35 In 
2009, Brockman et al simulated DBD and DCD scenarios 
in a porcine model. After 5 hours of preservation (NMP-L 
vs SCS), there was no difference seen in preservation 
method in either the DCD or DBD graft recipients. After 
20 hours of preservation, however, both DCD and DBD 
grafts that had been preserved using NMP-L were supe-
rior to their SCS counterparts with respect to enzyme 
release, histological changes and recipient survival. Of 
note, there was no difference in survival between DCD 
and DBD NMP-L-preserved graft recipients (83% and 
86%, respectively).36
Preclinical research and pilot study
Our team’s preclinical research on rejected human livers 
has demonstrated that metabolism of lactate, in combina-
tion with bile production, maintenance of physiological 
pH and stable blood flow rates are sensitive parameters 
predictive of organ viability. In April 2014, the UHBFT 
Novel Therapeutics Committee approved a pilot clinical 
project for transplantation of five reconditioned liver 
grafts, initially deemed unusable for transplantation. In 
this series, livers were declined by all the UK transplant 
units, after which NMP-L commenced following a vari-
able period of SCS. Still, five out of six tested livers met 
the viability criteria and were successfully transplanted.37 
Although this pilot project showed that viability testing 
has the potential to transform the organ selection and 
acceptance process of high-risk livers, our observation 
primarily provided the feasibility and short-term outcome 
data. In addition, this cohort also demonstrated the feasi-
bility of performing NMP-L within a ‘back-to-base’ model, 
that is, following SCS and inspection at the transplant 
centre. This offers logistical and financial advantages over 
using NMP-L in place of SCS and may target livers that 
would benefit the most from NMP-L. More research in 
this area is required, and this was recognised by the Health 
Innovation Challenge Committee of the Wellcome Trust 
who awarded our study group a research grant to fund 
this trial. We have demonstrated so far that a proportion 
of currently rejected liver allografts might be salvaged by 
subjecting them to NMP-L and viability testing. Use of this 
technology could transform the use of high-risk organs 
and may improve access to treatment for thousands of 
patients awaiting liver transplantation globally.
MEthods
study design overview
Viability testing and transplantation of marginal livers 
(VITTAL) is an open-label, non-randomised, prospec-
tive, single-arm trial, using NMP-L testing viability and 
transplantation of marginal livers. It is being conducted 
at a single site (UHBFT). The design uses two linked 
components assessing: (1) the feasibility of NMP-L as a 
technique to increase the number of transplantable livers 
and (2) achievement of successful transplantation of 
the NMP-L treated marginal livers. (1) uses a two-stage 
adaptive design,38 requiring up to 53 marginal livers to 
be perfused. (2) uses a three-stage adaptive design39 and 
requires 22 NMP-L treated marginal livers to be trans-
planted. Success is measured by a 90-day patient surviv-
al—a nationally accepted, monitored and continually 
audited outcome following liver transplantation.
Ethical and regulatory approval
The National Research Ethics Service (NRES) 
London-Dulwich (REC reference 16/LO/1056, Protocol 
number RG 15–240) and the Medicines and Health-
care Products Regulatory Agency (MHRA) approved 
all versions of the study protocol. This trial will use the 
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Figure 1 Patient and donor liver pathways. HA, hepatic artery; PV, portal vein; UHB, University Hospitals Birmingham; VITTAL, 
Viability testing and transplantation of marginal livers.
OrganOx metra device following a variable period of 
SCS to evaluate organ viability pretransplant procedure. 
The OrganOx metra device currently has a Conformité 
Européene (CE) mark for liver organ transport and not 
organ evaluation. The use of the device within this clin-
ical trial is therefore off registration and UK Competent 
authority (MHRA) clinical trial Investigation: No Objec-
tion was obtained (MHRA ref: CI/2016/0031. In addition, 
approval from the Research and Development (R&D) 
department at UHBFT and from National Health Service 
Blood and Transfusion (NHSBT’s) Research, Innovation 
and Novel Technologies Advisory Group (RINTAG) was 
obtained prior to the start of screening.
Graft entry into study and subsequent preparation
The patient and donor liver pathways can be seen in 
figure 1. All livers will be retrieved with the intention 
and standardised technique to use them for transplan-
tation. Following the retrieval procedure at the donor 
hospital the liver will be placed in ice-cold preservation 
solution on the back table and transported (according 
to local protocol). If the liver is allocated to UHBFT, 
if it is then considered not suitable for use it must be 
rejected by the on-call transplanting surgeon. For the 
liver to be considered untransplantable, the liver will be 
inspected by the on-call transplant surgeon and another 
transplant surgeon in the department. The liver will 
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Table 2 Trial sample collection schedule
Perfusate 
samples
Hepatic arterial and hepatic venous 
biochemistry (point of care)
Preperfusion
Every 30 min during perfusion
Cobas point-of-care desktop 
analyser
Perfusate supernatant Preperfusion
Every 15 min for first hour
Every hour thereafter
5×1 mL aliquots Stored at −80°C
Liver samples Liver biopsy L1 Preperfusion
L2 After 4 hours
L3 at end of perfusion*
L4 Postreperfusion
16 G core needle biopsy
Divided into segment for formalin, 
segment for frozen and piece for 
electron microscopy
Common bile duct CBD1 Preperfusion
CBD2 Postreperfusion
Formalin
Bile samples (If produced) B2 sample at 2 hours
B4 sample at 4 hours
B6 sample at 6 hours
Total volume recorded and 2 mL 





Visits 1, 2, 3, 4, extended follow-up Standard of care
Serum, plasma, mononuclear cells 
(PBMC)
Visit 1 (preoperative (postinduction 
of anaesthesia), postreperfusion
day 4 postoperative)
Visits 2, 3, 4,
Additional research samples




*If lasting longer than 6 hours.
PBMC, peripheral blood mononuclear cell.
then be offered as a fast track graft to the other centres 
around the UK. If rejected by all centres and if consent 
for research was taken, it will be considered for use in 
VITTAL. Livers offered to our unit as fast track offers 
from other centres will undergo the same two-consultant 
rejection process. An appropriate consented potential 
recipient will be selected by the transplant surgeon and 
contacted by the coordinator and will come into hospital 
for admission. The coordinator will request three units of 
packed red blood cells, matched to the intended recip-
ient, for use in the OrganOx metra device. The liver will 
be prepared according to the procedure for preparing 
the device for use and placing the organ on the device 
(described in detail in the OrganOx metra Instructions 
for Use (IFU) document (V.13.0, 12 March 2016). The 
liver will be weighed prior to being connected to the 
device. If cannulation proves impossible, the liver will 
be rejected as previously intended. If the liver meets the 
criteria for transplantation, the recipient explantation 
will commence and the procedure for removing the liver 
from the device is also described in the IFU. Implanta-
tion and reperfusion of the liver will proceed as per the 
usual practice of the implanting centre. The patient will 
be clerked as if they were being admitted for a standard 
liver transplant.
Perfusion of the graft
The machine will be primed with a perfusate suitable 
for NMP-L and will use packed red cells as the oxygen 
carrier. During the perfusion, biochemical analysis of the 
blood-based perfusate will be performed using a Cobas 
biochemical point-of-care analyser (Roche Diagnostics) 
which will give results for pH, pO2, pCO2, bicarb, base 
excess, calcium, chloride, sodium, potassium, haemo-
globin, haematocrit, lactate and glucose. Arterial and 
portal venous flows, resistances and pressures will also be 
recorded. Samples to be collected are detailed in table 2.
The duration of machine perfusion will be dictated by 
logistics and the recipient’s explant but should not be 
less than 4 hours or more than 24 hours. For a graft to be 
considered for transplantation it must meet at least 2 of the 
following criteria within 4 hours of the start of perfusion:
 ► Metabolise lactate to less than or equal to 2.5 mmol/L 
within 4 hours of the start of the perfusion;
 ► Demonstrate evidence of bile production;
 ► Maintain a pH greater than 7.30;
 ► Show evidence of glucose metabolism;
 ► Maintain stable hepatic arterial flow of more than or 
equal to 150 mL/min and portal flow more than or 
equal to 500 mL/min;
 ► Achieve homogeneous graft perfusion with soft 
consistency of the parenchyma.
Once the transplanting surgeon is content that the 
liver has met the criteria required for transplantation, the 
recipient will be brought to theatre and the explant will 
commence.
Explantation, implantation and reperfusion of the liver 
will be carried out in using standardised techniques by 
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the on-call transplant surgeon. The liver will remain on 
the machine until after the explantation has taken place 
at which point it will be flushed by 2 L of cold HTK imme-
diately prior to implantation.
concomitant therapy/medications
Patients will receive immunosuppression according to 
hospital protocols and other medications as necessary for 
their comorbidities and current clinical condition. Their 
postoperative care will be the same as if they had under-
gone a standard liver transplant.
objEctIvEs And outcoME MEAsurEs
Primary
There are two linked primary objectives and respective 
outcome measures:
Primary objective: (A) Establish the feasibility of NMP-L 
to increase the number of transplantable livers.
Primary Outcome measure: (A) ‘Rescue rate’ that is, 
the proportion of rejected livers that can be used for 
transplantation having been deemed viable following a 
period of machine perfusion.
Primary objective: (B) Achieve successful transplanta-
tion of previously rejected donor livers following viability 
testing using NMP-L.
Primary outcome measure: (B) 90-day patient survival, 
calculated as the number of patients alive 90-day post-
NMP-L-treated marginal liver transplantation (numer-
ator) divided by the total number of NMP-L-treated 
marginal liver transplants performed (denominator).
secondary
Secondary objective (1): Assessment of liver graft func-
tion following transplantation (by incidence of primary 
non-function and early allograft dysfunction).
Secondary outcome measures (1): Liver function tests; 
90-day graft survival; 12-month patient and graft survival.
Secondary objective (2): Assess morbidity associated 
with receipt of extended criteria graft that had previously 
been rejected.
Secondary outcome measures (2): Adverse event rates 
and severity, graded according to the Clavien-Dindo clas-
sification40 (see online supplementary file 1); Require-
ment of renal replacement therapy; incidence of biliary 
complications (including incidence of ischaemic-type 
biliary lesions diagnosed on magnetic resonance chol-
angiopancreatography (MRCP) at 6 months); incidence 
of vascular complications; biopsy-proven acute rejection; 
reoperation rate; length of intensive therapy unit stay and 
length of hospital stay.
Secondary objective (3): Assess the physiological 
response to reperfusion of the perfused grafts
Secondary outcome measures (3): Postreperfusion 
syndrome, defined as a decrease in mean arterial pres-
sure (MAP) of more than 30% from the baseline value for 
more than 1 min during the first 5 min after reperfusion 
(assessed in the context of inotrope use).
Secondary objective (4): Identify impact on quality of 
life (QoL) after transplantation with these liver grafts.
Secondary outcome measures (4): Quality of life by 
delivery of the EuroQoL 5 Dimensions 5 Levels question-
naire at baseline, day 30 and 6 months post-transplant.
AnALytIcAL MEthods
histopathology
Two independent liver histopathologists from UHBFT will 
perform all the histopathological assessments. Both will be 
blinded to the graft type and the primary and secondary 
outcome measures although the presence or absence of 
a postreperfusion biopsy means they will know whether a 
graft has met the criteria for transplantation. The histolog-
ical analysis will be established using H&E at two levels as 
well as periodic acid Schiff, periodic acid Schiff diastase, 
haematoxylin van Gieson, reticulin, orcein, rhodanin and 
Perls stains of formalin-fixed paraffin-embedded liver tissue.
Perfusion, clinical and laboratory data
Donor and patient demographics as well as intraoperative 
data will be collected. Body mass index (BMI) was defined 
as weight in kilograms divided by the square of the height 
in metres (kg/m2). In non-heart beating (DCD) donation, 
FWIT is defined as the time between the systolic blood 
pressure of the donor dropping below 50 mm Hg until the 
point of aortic perfusion. Cold ischaemic time is defined as 
the time between aortic perfusion and the start of NMP-L. 
DRI and Balance of Risk (BAR) will be calculated as per the 
relevant literature.11 41
The perfusate fluid will undergo point-of-care biochem-
ical testing every 30 min as previously described. Perfusate 
will be taken at the time-points described in table 2 and 
tested for transaminase, urea, albumin and factor V levels. 
Patient’s blood samples will be analysed for full blood 
count, urea, creatinine and electrolytes, liver function 
tests, prothrombin time, amylase, C-reactive protein and 
plasma glucose using standard laboratory methods (Roche 
Modular system, Roche, Lewes, UK) both preoperatively 
and postoperatively. Research recipient blood and urine 
samples will also be taken as part of WP2 that will enable 
immune cell profiling as well as lipodomic, proteomic and 
metabolomic testing.
Patient questionnaires
QoL will be assessed by delivery of the EQ-5D-5L question-
naire (UK (English) 2009 EuroQol Group EQ-5D is a regis-
tered trademark of the EuroQol Group) at baseline, day 
30 and 6 months’ post-transplant. EQ-5D-5L is a five-level 
version of the EQ-5D descriptive system (Herdman et al. Qual 
Life Res DOI 10.1007/s11136-011-99031). The 5L retains 
the 5-dimensional (5D) structure of the original EQ-5D-3L 
but the levels on each dimension were expanded to five 
based on qualitative and quantitative studies conducted by 
the EuroQol Group. Index-based values (‘utilities’) enable 
the calculation of quality-adjusted life years which help 
inform economic evaluations of healthcare interventions.
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stAtIstIcAL justIfIcAtIon And outcoME AnALysIs
sample size justification
For (A) feasibility of NMP-L to rescue discarded liver 
grafts, it is anticipated that NMP-L will achieve a desir-
able organ recovery rate of at least 50%, with an undesir-
able rate of 30% or less as this would not be considered 
economically feasible. The significance level (α) is set 
at 0.05, corresponding to the probability of incorrectly 
rejecting the hypothesis given it is true (type I error), 
and the power is set at 0.90 (type II error rate, β = 0.10
), corresponding to the probability of correctly deciding 
the NMP-L treatment is successful given the true response 
rate is greater than 50%.
Using a Simon’s two-stage design38:
Interim assessment stage 1A of accrual: 24 marginal 
grafts will be perfused and assessed in the first stage. 
Grafts will be transplanted depending on the criteria 
achieved. The procedure will be considered infeasible if 
there are fewer than eight recovered livers. If more than 
eight livers are transplanted, we will proceed to Stage 
2A.
Final stage 2A of accrual: Up to additional 29 marginal 
grafts will be perfused. We would consider the procedure 
feasible if there are at least 22 recovered livers out of 53 
perfused livers.
For (B) for viable livers transplanted following NMP-L, 
a desirable 90-day patient survival rate is at least 88%, 
with an undesirable rate of 73% (15% lower). The mean 
90-day patient survival rate for ‘standard’ liver transplants 
is 93%.42 An optimal three-stage design39 will be used 
to test the null hypothesis that the mean 90-day patient 
survival rate will be less than 73% (p≤0.73) versus an alter-
native hypothesis that the 90-day patient survival rate will 
be at least 88% (p≥0.88). The significance level is set at 
0.20 (target α=0.2), giving a 0.2 probability to conclude 
that a single transplantation is viable when it truly is not 
viable. The power is set at 80% (target β=0.2), giving a 
0.2 probability to conclude that a single transplantation is 
not viable when it truly is viable.
Interim assessment stage 1B: Following transplantation 
in three patients, the trial will stop early (concluding 
p≤0.73) if there are fewer than two patients achieving 
90-day survival. If two or more patients reach the primary 
end point of 90-day survival, an additional eight trans-
plantations will be performed.
Interim assessment stage 2B: Following transplantation 
in 11 patients (combined first and second stages) the 
trial will stop early (concluding p≤0.73) if there are 7 or 
fewer successes. If 8or more patients reach the primary 
end point, an additional 11 transplantations will be 
performed.
Final stage 3B: Following transplantation in 22 
patients in all three stages, the trial will be successful 
if at least 18 patients reach the primary end-point of 
90-day survival.
The trial schema is provided in figure 2.
Analysis of outcome measures
Primary analysis
To assess (A) the feasibility of NMP-L, the rescue rate 
will be calculated as the number of perfused marginal 
grafts meeting the criteria for viability (numerator) 




Number of viable perfused marginal grafts
Total number of perfused marginal grafts  
To assess (B)—achievement of successful transplanta-
tion of previously rejected donor liver following viability 
testing using NMP-L. We will evaluate 90-day patient 
survival rate as an indicator of liver function and/or 
viability following transplantation of marginal liver grafts 
following NMP-L. The 90-day patient survival rate will 
be calculated as the number of patients alive at 90-day 
post-transplant with a VITTAL graft, divided by the total 
number VITTAL patients transplanted.
 
90 day patient survival rate =
Number of patients alive at 90 days post transplantation
Total number of transplanations performed  
For (A), all livers undergoing NMP-L treatment will be 
included for evaluation in the interim and final analyses. 
For (B), all transplantations performed will be included 
for evaluation in the interim and final analyses. The rate 
outcomes will be reported together with confidence inter-
vals using the Wilson (1927) method.43
Planned interim assessments
As we have used adaptive designs, there are planned 
formal interim assessments for both (A) feasibility of 
NMP-L and (B) successful transplantation of rescued 
livers, with clear ‘Go’/‘No go’ decisions as detailed 
earlier. Ideally, recruitment (ie, transplantation) would 
stop while interim analyses of the primary outcome 
measures are performed. For (A), this could happen 
immediately, however for (B), this would result in a 
pause of over 3 months hence the pragmatic approach 
for such adaptive designs is to continue recruitment 
while they are being conducted.
To maximise patient safety, for (B) at the end of the 
first stage (transplantation of the first three patients), 
recruitment will be paused to allow the Data Monitoring 
Committee (DMC) to assess the initial safety data. Once 
all three patients are discharged, if the DMC considers 
the patients to be recovering well, with liver function 
that would be expected at this stage, recruitment can 
continue prior to the patients reaching the primary 
endpoint of 90-day survival. A follow-on report will be 
sent to the DMC once the third patient reaches the 
primary end-point. For the second stage (transplanta-
tion of 11 patients), safety data will be sent to the DMC 
for review after discharge of all 11 patients however 
recruitment need not stop at this point. A follow-on 
report will again be sent once the 11th patient reaches 
the primary end-point.
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Figure 2 Trial schema. VITTAL, Viability testing and transplantation of marginal livers.
Additional DMC meetings will be conducted on request 
if the success criteria are not met. If recruitment is fast, 
prompt reviews will be necessary to ensure the use of 
interim decisions.
Secondary analysis
For all secondary outcome measures, analyses will be 
mainly descriptive. Continuous exploratory measures will 
be summarised via means, medians, SD and ranges. Cate-
gorical measures will be summarised with number and 
proportion in each category. To model repeated measures 
over time (eg, QoL), a linear mixed effects model (consid-
ering subject correlation) using parametric and more flex-
ible models may be considered. Time-to-event outcomes 
will be assessed using the method of Kaplan and Meier. 
Median survival with corresponding 95% CI will also be 
reported where appropriate. The assessment of graft func-
tion post-transplantation by incidence of primary non-func-
tion and early allograft dysfunction will be carried out by 
comparing results with a contemporary matched recipient 
group of patients obtained from a prospectively maintained 
database, with adjustment for potential confounders.
The contemporary matched recipient group will be 
matched using the following:
 ► Patient characteristics: age, sex, BMI, model for 
end-stage liver disease (MELD), UK end-stage liver 
disease (UKELD), aetiology;
 ► Donor liver characteristics: DCD or DBD, sex.
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Suitable donor liver grafts will be selected from October 
2016. Grafts will be retrieved with the intention to trans-
plant and rejected as previously described.
Graft inclusion criteria
Rejected donor liver grafts must meet all of the following 
inclusion criteria to be eligible for inclusion in the 
VITTAL trial:
 ► Liver from a donor primarily accepted with the inten-
tion for clinical transplantation;
 ► Rejected by all the other UK transplant centres via 
normal or fast-track sequence;
 ► Cold ischaemic time less than 16 hours for DBD and 
10 hours for DCD grafts;
 ► One of the following parameters which would denote 
the marginal condition of the liver:
 – Donor risk index greater than 2.011;
 – Graft macrovesicular steatosis greater than 30%;
 – BAR score greater than 944;
 – Donor warm ischaemic time greater than 30 min;
 – Anticipated cold ischaemic time greater than 
12 hours for DBD or 8 hours for DCD liver grafts;
 – Suboptimal liver graft perfusion documented by a 
photo of macroscopic appearance;
 – Donor transaminases (aspartate transaminase 
(ALT) or alanine transaminase (AST)) above 1000 
IU/mL.
Graft exclusion criteria
Livers meeting any of the following criteria would not be 
suitable for the VITTAL trial:
 ► Grafts from patients with active Hepatitis B, C or HIV 
infection;
 ► Livers with macroscopic appearance consistent with 
cirrhosis;
 ► Livers with advanced fibrosis;
 ► DCD grafts with donor warm ischaemic time (systolic 
blood pressure less than 50 mm Hg to aortic perfu-
sion) more than 60 min;
 ► Excessive cold ischaemic times (DBD more than 
16 hours / DCD more than 10 hours);
 ► Paediatric donor (<18 years);
 ► ABO (blood group) incompatibility.
recipient inclusion criteria
Suitable potential VITTAL graft recipients will be iden-
tified during the listing process. Patients will be told 
that they are potentially suitable to receive a graft from 
the VITTAL trial and will be given the patient infor-
mation sheets to read more about the trial. If already 
listed, potential recipients will be identified on the list, 
contacted and sent the same documentation. If they wish 
to take part, a minimum of verbal consent will be taken. 
Enrolling in the trial will in no way impact on the chance 
of them receiving a standard ‘transplantable’ graft. 
Patient’s with all aetiologies of chronic liver disease will 
be considered for inclusion. Listed patients must meet all 
of the following inclusion criteria to be eligible for partic-
ipation in the VITTAL trial:
 ► Adult primary liver transplant recipient;
 ► Patient listed electively for transplantation;
 ► Low to moderate transplant risk candidate, suitable for 
marginal graft, as assessed by the UHBFT liver trans-
plant listing multidisciplinary team (MDT) meeting 
(these are usually candidates with low UKELD score, 
without cardiovascular comorbidities, with good func-
tional and nutrition status, with patent portal vein and 
with no history of previous major upper abdominal 
surgery, for example, patients transplanted for liver 
cancer);
 ► There is no lower limit for MELD or UKELD. Upper 
UKELD is discussed in the exclusion criteria below.
recipient exclusion criteria
Subjects who meet any of the following exclusion criteria 
are excluded from participating in the VITTAL trial:
 ► ‘High-risk patients’ and recipients not considered 
suitable for a marginal graft (these are mainly patients 
with high UKELD score (>62 as per the NHSBT Liver 
Advisory Group (LAG) criteria for graft sharing in 
high-risk recipients in the North East of the UK with 
cardiovascular comorbidities or renal insufficiency, 
with poor nutrition and performance status or history 
of major upper abdominal surgery, for example, 
patients listed for liver retransplantation) (http://
www. odt. nhs. uk,/ search ‘Liver Allocation Policy’);
 ► Patients with complete portal vein thrombosis diag-
nosed prior to the transplantation;
 ► Liver retransplantation;
 ► Patients with fulminant hepatic failure;
 ► Patients undergoing transplantation of more than 
one organ;
 ► Contraindication to magnetic resonance imaging (ie, 
pacemaker fitted).
Adverse events reporting and analysis
The collection and reporting of adverse events (AEs) will 
be in accordance with the Research Governance Frame-
work for Health and Social Care and the requirements of 
the National Research Ethics Service (NRES). Definitions 
of different types of AEs are listed in online supplemen-
tary file 1. The reporting period for AEs will commence at 
visit 1 and end at the 24-month follow-up. The Investigator 
should assess the seriousness and causality (relatedness) 
of all AEs experienced by the patient (this should be docu-
mented in the source data) with reference to the protocol. 
This will include abnormal laboratory findings which are 
reported as clinically significant. All AEs, device deficien-
cies and adverse device event (ADEs) will be reported 
using the applicable electronic case report form (eCRF). 
AEs will be reported in accordance with Clavien-Dindo 
classification of surgical complications.40 Anticipated 
AEs include those related to any form of major surgery; 
infection (chest, urine, blood, bile, wound, abdominal), 
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fluid collection (abdominal, pleural), renal dysfunction, 
cardiac failure, respiratory failure and those related to 
the disease process and transplantation; early allograft 
dysfunction, rejection, hospitalisation for pre-existing 
condition that has not deteriorated, clinically significant 
abnormal laboratory finding or other abnormal assess-
ments that is associated with the condition being studied 
(unless judged by the investigator as more severe than 
expected for the patient’s condition). The investigator will 
exercise his/her medical judgement in deciding whether 
an abnormal laboratory finding or other abnormal assess-
ment is clinically significant. However, if in the opinion of 
the investigator, the frequency or severity of the event is 
greater than would be expected then it must be reported. 
Device deficiencies that did not lead to an adverse event 
but could have led to a medical occurrence if suitable 
action had not been taken or intervention had not been 
made or if circumstances had been less fortunate will also 
be recorded and reported.
those events not being reported
The following are considered routine during or after liver 
transplantation and will not be reported as AEs.
 ► Initial admission to intensive care following liver 
transplant;
 ► Elevation of AST and/or ALT<2000 iu/mL within 
48 hours of liver transplant;
 ► Transfusion of ≤5 units of packed red cells;
 ► Transfusion ≤8 units of fresh frozen plasma;
 ► Transfusion ≤2 adult doses of platelets.
In addition to the above, medical and scientific judge-
ment should be exercised in deciding whether expe-
dited reporting is appropriate in other situations, such 
as important medical events that may not be immedi-
ately life threatening or result in death or hospitalisation 
but may jeopardise the patient or may require interven-
tion. Any death occurring during the protocol defined 
follow-up period (within 90 days), whether considered 
device related or not, must be reported as an SAE within 
24 hours of the local investigator becoming aware of the 
event. If a death occurs in a patient receiving a transplant, 
the cause of death will be investigated and reviewed by 
the Trial Management Group (TMG) and clinical team 
caring for the patient. Entry of patients in to the study 
would be temporarily suspended until these investiga-
tions are complete.
study visit overview
The VITTAL trial involves a minimum of four patient 
visits which all coincide with standard admissions either 
for surgery or for outpatient follow-up. There are no 
additional trial-specific visits. The schedule for the study 
visits and data collection is summarised in table 3. Visit 1 
encapsulates admission for transplant and the postoper-
ative period if the transplant proceeds. Visits 2, 3 and 4 
are scheduled for 30-day, 90-day and 180-day follow-up, 
respectively. All patients will undergo MRCP during visit 
4 to investigate the occurrence of ischaemic-type biliary 
lesions which also marks trial end-point. Patients will 
continue to be followed up at 12 months and 24 months 
as part of their standard post-transplant care, and data will 
be collected at these time-points for long-term reporting.
storage of samples
Patient blood samples taken as part of their standard of 
care will be processed and stored according to UHBFT 
procedures. Perfusate, patient serum, plasma, urine 
samples and mononuclear cell preparations collected 
during visits 1–4 will be stored frozen in 0.5–1.0 mL 
aliquots at – 80°C at the Institute of Biomedical Research, 
University of Birmingham. Liver biopsy tissue speci-
mens will be collected and the formalin fixed paraffin 
embedded segments will be processed by staff in the 
department of cellular pathology at UHBFT. After 
sectioning and staining, tissue blocks will be stored at 
the Institute of Biomedical Research. All samples will be 
collected in accordance with national regulations and 
requirements including standard operating procedures 
for logistics and infrastructure. Samples will be taken in 
appropriately licensed premises, stored and transported 
in accordance with the Human Tissue Authority guide-
lines and trust policies.
data handling, quality assurance, record keeping and 
retention
Data will be managed according to the standard oper-
ating procedures of the Cancer Research UK Clinical 
Trials Unit (CRCTU) at the University of Birmingham, 
UK. The CRCTU is fully compliant with the Data Protec-
tion Act 1998 and the Guidelines for Good Clinical 
Practice. The CRCTU will monitor the trial and provide 
annual reports to the MHRA. The trial is registered 
with the Data Protection Act website at the University 
of Birmingham. Donor and patient details will be kept 
anonymous (specific study identification codes will be 
used for each study donor). Anonymised donor data will 
be used in future publications arising from the study. 
Patients will be identified using only their unique regis-
tration number, patient initials on the case report form 
and correspondence between the trials office and the 
participating site. In addition, the patients are requested 
to give permission for the trials office to be sent a copy 
of their signed Informed consent form which will not 
be anonymised. This will be used to perform in-house 
monitoring of the consent process. Identifiable data will 
only be made available to authorised staff of the study 
sponsor, its authorised representatives and regulatory 
authorities. All patients will be consented specifically to 
enable data to be shared as detailed above. Confidenti-
ality will otherwise be maintained throughout the trial 
and thereafter and data will be anonymised. On comple-
tion of the trial, data will be transferred to a secure 
archiving facility at the University of Birmingham, where 
data will be held for a minimum of 15 years and then 
destroyed.
group.bmj.com on March 20, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 



























































































































































































































































































































































































































































































































































































































group.bmj.com on March 20, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 13Laing RW, et al. BMJ Open 2017;7:e017733. doi:10.1136/bmjopen-2017-017733
Open Access
Electronic case report forms
Electronic case report forms (ECRFs) have been 
designed to capture as much, donor, perfusion and 
patient data as possible and feasible. The liver regis-
tration form and donor history form detail all that is 
relevant regarding the quality of the graft itself. The 
perfusion form enables collection of the perfusion 
parameters, biochemical data and the outcome of the 
perfusion. The patient registration and visit 1 forms 
will capture the demographics of the recipient as well 
as track the operative and postoperative course. Visits 
2–4 are for patient follow-up.
trial organisational structure
The University of Birmingham will act as single sponsor 
this single-centre study. The trial is being conducted 
under the auspices of the CRCTU, The University of 
Birmingham according to their local procedures. The 
TMG will be responsible for the day-to-day running and 
management of the trial. Members of the TMG include 
the chief investigator, coinvestigators, project manager, 
trial management team leader, senior trial coordinator, 
trial coordinator, lead trial statistician and trial statistician. 
The TMG will have regular meetings during recruitment. 
The DMC will consist of independent clinicians Professor 
James Neuberger, Mr Gabi Oniscu and Professor Jacques 
Pirenne as well as an independent statistician, Mr Andrew 
Hall. Data analyses will be supplied in confidence to the 
independent DMC, which will be asked to give advice on 
whether the accumulated data from the trial, together 
with the results from other relevant research, justifies the 
continuing recruitment of further patients. The DMC 
will operate in accordance with a trial specific charter 
based on the template created by the Damocles Group. 
The DMC will meet at two scheduled time-points after 
the interim analyses as previously described (figure 2). 
An emergency meeting may also be convened if a safety 
issue is identified. The DMC will report directly to both 
the VITTAL Trial Management Group (chief investi-
gator) who will convey the findings of the DMC to the 
trial steering group and funders/sponsor as appropriate 
or when specifically requested by these parties.
sources of funding
The VITTAL trial is funded by a grant awarded by the 
Wellcome Trust Health Innovation Challenge Fund 
(awarded December 2015).
trial status
Recruitment for the trial opened in October 2016 and 
recruitment is expected to last 24 months.
dIscussIon
The consequence of the escalating demand for liver trans-
plantation is increasing waiting list mortality, and in many 
countries, patients are more likely to die while waiting for 
an organ than in the first year after their transplant.45 The 
outcomes of high-risk livers are inferior to standard grafts 
and the difference is most noticeable within the initial 
90 days. Indeed, severe early allograft dysfunction or 
primary non-function often trigger post-transplant sepsis 
and multiorgan failure and as consequence, livers with 
marginal features are often declined and discarded.
Our preliminary experience and pilot transplant 
series showed NMP-L can provide objective information 
regarding liver function and the VITTAL trial aims to 
produce robust data and validate our initial observations.
Several challenges were identified when designing the 
VITTAL trial with the foremost being to create a sound 
definition of a discarded liver. There is an undeniable 
variation in use of high-risk livers among the UK trans-
plant centres which has been recognised and highlighted 
by NHSBT. The organisation published ‘Taking organ 
transplantation to 2020’, a strategy that aims to create 
greater consistency in the acceptance of organ offers and 
use of marginal livers across all centres.46 To address this 
issue for this study purposes, every declined liver offered 
for enrolment into VITTAL has to meet also at least 
one of a list of predefined, constant inclusion measures, 
adopted in combination with a two-consultant system of 
macroscopic liver quality assessment.
The most important factor to consider while designing a 
trial that pushes the current boundaries of high-risk livers 
use is patient safety. Although we opted for liberal liver 
graft selection inclusion criteria, only low to moderate 
risk recipients are eligible to take part in this trial. Such 
an approach has been shown previously to be the safest 
and the most successful strategy for use of high-risk 
organs.41 47 The intended recipients will be risk stratified 
and selected by the liver unit’s liver transplant multidisci-
plinary team. Another important trial safety feature is its 
3-stage adaptive design, introducing 2 interim safety anal-
yses after completion of 3 and 11 transplants, respectively.
There are undoubtedly some livers that will not be 
salvageable or ever safe to transplant. It is important 
for the purposes of the trial to include organs that fail 
to meet the defined viability criteria to compare these 
with transplantable high-risk livers. The research work 
package linked with the trial was designed to identify 
sensitive point-of-care liver quality tests and propose 
novel biomarkers or panels associated with viable livers.
The primary end-point of 90-day patient survival has 
been chosen as it is a nationally accepted, monitored and 
continuously audited outcome following liver transplan-
tation. Obviously, the graft survival rate is important and 
for the trial to truly be successful, patients who reach the 
primary end-point should have a VITTAL graft still in 
situ. This will be considered when the DMC monitor the 
results at the interim analyses.
As well as the study design, challenges with trial logistics 
were also identified. One of the previously unseen diffi-
culties after discussion with the haematology team is the 
issuing of packed red cells matched to the intended recip-
ient, potentially before the patient is admitted to hospital, 
to avoid delaying the start of the perfusion. When patients 
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are listed, they undergo a blood cross-matching process 
to identify blood group and the presence of antibodies. 
This sample is not held for longer than 7 days by the 
hospital and so if they are admitted for a transplant or 
require blood products for some other intervention, they 
have a new sample sent before those products are issued. 
In the case of the VITTAL trial, a perfusion may need 
to commence before the patient is admitted to hospital 
as they may have to travel some distance. Minimising the 
cold ischaemic time of marginal grafts is paramount to 
improve the chances of graft salvage. Therefore, in this 
scenario, blood is issued for the trial based on the results 
of the original sample and a repeat is sent when the 
patient is admitted to check they have not subsequently 
developed new antibodies. Blood product traceability is 
an important consideration and the blood products are 
documented to have been used in the device perfusate 
only and have not been used for recipient transfusion.
EthIcs And dIssEMInAtIon
The VITTAL Clinical trial is an academic investigator-led 
study involving a CE marked medical device. The device is 
being used outside it current CE mark and therefore has 
been reviewed by the MHRA UK and received a ‘clinical 
investigation: no objection’ (CI/2016/0031) letter: 3 August 
2016. In addition, the study has undergone national ethical 
review in the UK and received national ethical approval 
from the London—Dulwich Research Ethics Committee 
(16/LO/1056) and the Health Research Authority. In 
addition to the above national regulatory approvals, the 
study has been reviewed by NHSBT service and received all 
appropriate local institution/NHS R&D approvals. The trial 
management team are also fully engaged in an academic 
collaboration with the device manufacture OrganOx as 
part of the management of this study.
The trial management team are fully committed to 
publishing (within 12 months of the end of the study) the 
results of this study in accordance with best clinical practice 
in an open-access, peer-reviewed medical journal irrespec-
tive of outcome. Any dissemination of results or publicity 
will be provided in a format which will not allow individual 
patients to be identified and confidentiality will be main-
tained throughout the process. The study management 
will be conducted in accordance with all applicable clin-
ical trial regulations and managed centrally by the Drugs, 
Devices, Diagnostics and Biomarkers (D3B) trial manage-
ment team— part of the Cancer Research UK(CRUK) clin-
ical trials unit based in Birmingham in accordance with the 
quality management system. The results of the study will 
also be made available directly to study participants and 
specialist patient groups.
suMMAry
The presented VITTAL trial is the first clinical trial 
designed to objectively assess function of declined livers 
using NMP-L and subsequently transplanting viable 
grafts. It is hoped that the trial will identify a proportion 
of discarded organs that can be successfully transplanted 
and the generated data will provide objective and vali-
dated information that can be subsequently implemented 
in the process of acceptance and allocation of high-risk 
donor livers. This novel approach should improve consis-
tency and increase use of marginal liver grafts without 
compromising recipient safety.
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